$10M for Tetraphase


Watertown, MA-based Tetraphase Pharmaceuticals has raised $10 million out of a planned $29.6 million equity financing round, according to regulatory documents filed Wednesday. The Harvard spinoff, which is using synthetic chemistry to develop new antibiotics for drug-resistant infections, previously raised $25 million in two tranches that closed in August 2008.

Wade Roush is Chief Correspondent and Editor At Large at Xconomy. You can subscribe to his Google Group or e-mail him at wroush@xconomy.com. Follow @

By posting a comment, you agree to our terms and conditions.